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Abstract: Three-dimensional spheroids of non-malignant MCF10A and malignant SKBR3 breast cells
were used for subsequent 3D Cell-SELEX to generate aptamers for specific binding and treatment
of breast cancer cells. Using 3D Cell-SELEX combined with Next-Generation Sequencing and
bioinformatics, ten abundant aptamer families with specific structures were identified that selectively
bind to SKBR3, and not to MCF10A cells. Multivalent aptamer polymers were synthesized by
co-polymerization and analyzed for binding performance as well as therapeutic efficacy. Binding
performance was determined by confocal fluorescence imaging and revealed specific binding and
efficient internalization of aptamer polymers into SKBR3 spheroids. For therapeutic purposes, DNA
sequences that intercalate the cytotoxic drug doxorubicin were co-polymerized into the aptamer
polymers. Viability tests show that the drug-loaded polymers are specific and effective in killing
SKBR3 breast cancer cells. Thus, the 3D-selected aptamers enhanced the specificity of doxorubicin
against malignant over non-malignant breast cells. The innovative modular DNA aptamer platform
based on 3D Cell SELEX and polymer multivalency holds great promise for diagnostics and treatment
of breast cancer.
Keywords: aptamer; breast cancer; SKBR3; spheroids; doxorubicin; multivalency
1. Introduction
Breast cancer is the most frequently diagnosed type of cancer among women, as well
as the leading cause of cancer death. World-wide, over two million new cases of breast
cancer were estimated in 2018, accounting for nearly 25% of all cancer cases, and over
600,000 deaths were reported due to breast cancer [1]. Breast cancer is a highly heteroge-
neous disease, and several classifications for identifying subtypes of breast cancer have
been developed, based on histological and molecular markers [2]. Currently, several sub-
types are classified for medical practice, which are mainly distinguished on the basis of the
expression of three key receptors: The hormone receptors estrogen (ER) and progesterone
(PR), and the human epidermal growth factor 2 (HER2). Adjuvant treatment is based on
these subtypes, and may consist of anti-hormonal, anti-HER2, and/or chemotherapy [2].
Chemotherapy, often consisting of doxorubicin, sometimes combined with cyclophos-
phamide and/or 5-fluorouracil, is, however, limited by toxicity [3] and lacks specificity.
Therefore, continued research is necessary for further development of drugs, designed
to target specific breast cancer cells as well as for developing novel tools for monitoring
patients and early detection of breast cancer.
Aptamers are single-stranded DNA or RNA oligonucleotides that can be generated
using a selection process called SELEX (Systematic Evolution of Ligands by EXponential
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enrichment) to specifically bind with high affinity to molecular targets [4,5]. Aptamers
can be selected for virtually every possible target, including metal ions, small molecules
such as drugs or peptides, proteins, viruses, bacteria, whole cells, or even targets within
living animals (reviewed in [6–9]). The affinity and specificity of aptamers is comparable to
traditional antibodies, and aptamers are a proven alternative to antibodies for activating or
inhibiting processes, or to serve as vehicles for targeted delivery of imaging or therapeutics
agents. Moreover, compared to antibodies, aptamers have several advantages, such as
ease of synthesis, modification and functionalization, high stability, and low toxicity and
immunogenicity. This makes aptamers ideal tools for the development of novel strategies
in selective diagnostics and therapeutics of cancer.
Aptamers have been generated using traditional SELEX technology against purified
proteins or whole cells to select for targets exposed on cell surfaces. In this study, we
used 3D spheroids as targets for the SELEX procedure to generate aptamers against tumor
cells in a more physiologically relevant microenvironment. We identified DNA aptamers
that bind with high affinity and specificity to SKBR3 spheroid breast cancer cells. Using a
modular polymeric approach, we constructed multivalent aptamer polymers with DNA
boxes carrying doxorubicin payloads that are effective and specific in killing target breast
cancer cells. The 3D spheroid cell SELEX and modular synthesis approaches hold great
promise as novel strategies for developing tools for cancer diagnostics and therapeutics.
2. Results
2.1. Selection of Aptamers against SKBR3 Spheroids
A novel 3D Cell-SELEX procedure was used to generate DNA aptamers, using tight
and compact spheroids of SKBR3 breast cancer cells as target [10]. Multicellular tumor
spheroid models have been widely used to mimic the three-dimensionality of solid tu-
mors [11]. However, with one exception, i.e., for selection of aptamers against prostate
cancer cells [12], spheroids have so far not been used as targets for selection of aptamers.
Compact, tight spheroids of SKBR3 breast cancer cells were used as targets and non-
malignant MCF10A breast epithelial cells for negative selection during the SELEX proce-
dure. Spheroids were grown in U-shaped 96-well plates using the liquid overlay technique
with Matrigel addition [10]. For the selection process, we used a 91 nucleotide DNA
oligonucleotide containing two 23-nucleotide random sequences (Supplementary Table S1).
The two random regions were separated by a stable GAA hairpin loop to force the aptamers
into a more stable fold for enhanced binding. In the first two rounds of the selection proce-
dure, the aptamer pool was targeted to monolayers of SKBR3 cells and control MCF10A
cells, grown to confluency. From the third round on, spheroids were used for selection.
A total of 12 rounds of SELEX were performed (Supplementary Table S2), after which
sequences were analyzed using Next Generation Sequencing (NGS) methods. First, the top
100 most frequent sequences were grouped in families based on sequence homology with
the top 10 most frequent sequences using the program ClustalX (Table 1, Supplementary
Table S3) [13]. Secondary structures of the 10 most frequent sequences of the final round
were analyzed using M-Fold [14]. This analysis shows formation of stable double-stranded
regions connected by internal and hairpin loops, as well as large unstructured regions
(Supplementary Figure S1). The sequences can be grouped in 10 different families based on
distinct secondary structure features. Samples of all rounds were sequenced to monitor the
selection process. As can be seen in Figure 1, the sequence space converges after round 6,
finally resulting in 5 dominant species, which are already present at 0.04 – 0.2% in the first
few rounds. In the final round the top 5 most frequent sequences account for 40% of all
sequences (Supplementary Table S4).
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Table 1. Top 10 of raised aptamer sequences after 12 rounds of selection.











1 Sequences in red indicate the constant adapter regions for amplification and the internal hairpin.
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The stable secondary structures of the 5 dominant sequences, of which each structure 
represents one distinct structural family, are shown in Figure 2. Interestingly, only one 
sequence, SKBR3-R2, is predicted to form the input stable GAA hairpin loop, and the hair-
pin sequence is partially deleted in SKBR3-R1. This illustrates the power of selection from 
a library of random sequences, which apparently overrules rational design.  
For in vivo applications and labeling strategies for imaging and stability purposes, 
the availability of short sequences, without compromising affinity and specificity, is an 
important issue. Further secondary structure analysis revealed common structural signa-
tures among the different families. Assuming that affinity and specificity of aptamers de-
pend on their specific shapes [5,15,16], these common structural signatures can be used to 
Figure 1. Graphical representation of the enrichment of the top 5 raised aptamer sequences in each
round of the selection procedure.
The stable secondary structures of the 5 dominant sequences, of which each structure
represents one distinct structural family, are shown in Figure 2. Interestingly, only one
sequence, SKBR3-R2, is predicted to form the input stable GAA hairpin loop, and the
hairpin sequence is partially deleted in SKBR3-R1. This illustrates the power of selection
from a library of random sequences, which apparently overrules rational design.
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Figure 2. (A) Predicted secondary structures of the top 5 raised aptamers. Structures were obtained with the DNA folding
module on the Mfold webserver [14] sing ionic strength conditions of 150 mM NaCl and 5 mM Mg2+ at 20 ◦C. ucleotides
in red originate from library design. (B) Predicted secondary structures of truncated SKBR3-R1 and SKBR3-R2 aptamers
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For in vivo applications and labeling strategies for imaging and stability purposes,
the availability of short sequences, without compromising affinity and specificity, is an
important i ue. Further secondary s ructure analysis reveal d c mmon structural sig-
natures among the different families. Assuming that affinity and specificity of aptamers
depend on their specific shapes [5,15,16], these common structural si natures can be used
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to design truncated versions of the selected aptamers. The truncated versions, obtained
by omitting the flanking constant sequences used for amplification and sequencing, are
also shown in Figure 2. SKBR3-R1Tr, which is a derivative of SKBR3-R1, was designed
because it represents the most abundant selected sequence (22.9% in the final, 12th round).
SKBR3-R2Tr was designed because of its atypical loop motif. These truncated versions
were used for most further studies.
2.2. Affinity and Specificity of Aptamers
To assess the affinity and specificity of the selected aptamers for cancer cells, DNAs
were synthesized with a 3’ribose for labeling with fluorescent dyes (Alexa Fluor 488 or 594)
using NaIO4–hydrazide chemistry. Specificity of aptamer binding to 3D spheroids of target
SKBR3 cells and control MCF10A cells was initially assessed using fluorescence microscopy
(Figure 3). The full SKBR3-R1 aptamers efficiently bind to the target SKBR3 breast cancer
cells, as shown by formation of tight coronas of bound fluorescent aptamers around the
target cells after 1 h incubation at room temperature (Figure 3A, Supplementary Figure S2).
The control MCF10A do not show formation of coronas of fluorescence around the cells,
indicating absence of binding. Here, the fluorescent aptamers do not bind to the cells in
the spheroids, but only freely diffuse in the channels formed in between the spheroid cells
(Figure 3B). A randomized aptamer (Scramble-AF594) that was used as control, did not
show binding to either SKBR3 or MCF10A spheroids (Supplementary Figure S3). To further
illustrate the affinity of the selected aptamers for target SKBR3 cells, the binding affinity of
SKBR3-R1Tr to SKBR3 spheroids was determined by serial dilution of the aptamer. The
data reveal high affinity with a Kd of 81.4 nM (Supplementary Figure S4).




Figure 3. Images of spheroids incubated with full SKBR3-R1 aptamers labeled with Alexa Fluor 
594 after one hour incubation at room temperature. Images on the left are at 10×, images in the 
middle at 10× magnification, bright field, and AF594 signal (red). The images on the right show 
Hoechst-stained nuclei (cyan) and the AF594 signal (red). Panel (A), SKBR3 spheroids. Panel (B), 
MCF10A spheroids. 
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The observed specificity of binding shows the potential of the aptamers as an im-
portant tool for diagnostics of breast cancer involving SKBR3 cells, a cell line representa-
tive of HER2+ breast cancer. However, for therapeutic purposes such as drug delivery or 
siRNA delivery using aptamers as a carrier, it is important to show that the selected ap-
tamers are internalized into the target cells after binding [17]. Therefore, further fluores-
cence microscopy experiments were performed to investigate if the aptamers internalize 
into target cells. At 37 °C, the SKBR3-R1Tr aptamers readily internalize into SKBR3 sphe-
roid cells, as shown by the typical punctate pattern of a large number of clear fluorescent 
spots in the microscope images after 24–48 h of incubation (Figure 4A). The aptamers do 
not internalize into control MCF10A cells, but also here only freely diffuse in the channels 
formed inside the spheroid. The control, randomized aptamer Scramble-AF594 did not 
internalize into SKBR3 spheroids (Supplementary Figure S5). Specificity of binding is fur-
ther illustrated by internalization of SKBR3-R1Tr aptamers into SKBR3 cells grown as 2D 
monolayers and complete absence of internalization into control MCF10A cells grown in 
2D (Figure 4B). Importantly, the intensity of aptamers bound to SKBR3 cells in 2D tissue 
cultures is apparently considerably lower than 3D spheroids, indicating higher affinity for 
cells in 3D spheroids. To investigate the mechanism of internalization, experiments were 
conducted using fluorescent-labelled dextran, which is a marker of macropinocytosis 
[18,19]. Fluorescent-labelled dextran is taken up by the target SKBR3 cells as well as con-
trol MCF10A cells (Supplementary Figure S6). Fluorescent-labelled aptamers mixed with 
fluorescent-labelled dextran are only taken up by SKBR3 and co-localize with the dextran 
label, indicating a macropinocytosis type of mechanism for internalization. 
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2.3. Internalization of Aptamers
The observed specificity of binding shows the potential of the aptamers as an impor-
tant tool for diagnostics of breast cancer involving SKBR3 cells, a cell line representative of
HER2+ breast cancer. However, for therapeutic purposes such as drug delivery or siRNA
delivery using aptamers as a carrier, it is important to show that the selected aptamers
are internalized into the target cells after binding [17]. Therefore, further fluorescence
microscopy experiments were performed to investigate if the aptamers internalize into
target cells. At 37 ◦C, the SKBR3-R1Tr aptamers readily internalize into SKBR3 spheroid
cells, as shown by the typical punctate pattern of a large number of clear fluorescent spots
in the microscope images after 24–48 h of incubation (Figure 4A). The aptamers do not
internalize into control MCF10A cells, but also here only freely diffuse in the channels
formed inside the spheroid. The control, randomized aptamer Scramble-AF594 did not
internalize into SKBR3 spheroids (Supplementary Figure S5). Specificity of binding is
further illustrated by internalization of SKBR3-R1Tr aptamers into SKBR3 cells grown as
2D monolayers and complete absence of internalization into control MCF10A cells grown
in 2D (Figure 4B). Importantly, the intensity of aptamers bound to SKBR3 cells in 2D tissue
cultures is apparently considerably lower than 3D spheroids, indicating higher affinity
for cells in 3D spheroids. To investigate the mechanism of internalization, experiments
were conducted using fluorescent-labelled dextran, which is a marker of macropinocyto-
sis [18,19]. Fluorescent-labelled dextran is taken up by the target SKBR3 cells as well as
control MCF10A cells (Supplementary Figure S6). Fluorescent-labelled aptamers mixed
with fluorescent-labelled dextran are only taken up by SKBR3 and co-localize with the
dextran label, indicating a macropinocytosis type of mechanism for internalization.
2.4. Drug Delivery Using Polymeric Payloads
Doxorubicin (Dox) is one of the most potent chemotherapeutic drugs developed, and
has been used in a variety of anticancer treatment including breast cancer [20]. Dox acts
by intercalating DNA, which causes disruption of DNA replication and finally results
in apoptotic cell death. Unfortunately, the treatment of breast cancer using systemic
administration of Dox is severely hampered by limited maximal dosage, acquired drug
resistance, and serious side effects, in particular cardiotoxicity [3]. The mechanism of
Dox toxicity, however, which involves intercalation of specific DNA sequences, can be
harnessed for targeted delivery of Dox using DNA aptamer technology. Aptamers can be
extended with short hairpins or double stranded DNA regions containing CpG stretches,
which are known to efficiently intercalate Dox [21–24]. Instead of extending aptamers
with DNA Dox carriers for targeted delivery, which has been the approach by various
laboratories [25–35], here we use a modular approach, where we combine Dox carriers with
high payload capacity with our selected aptamers using polymer synthesis, as schematized
in Figure 5.
Polyacrylamide was used as the polymer backbone based on its stability and biocom-
patibility [36,37]. Acrydite-modified oligonucleotides were used to incorporate aptamers
and Dox carriers (Dox boxes) into polyacrylamide during polymerization. Three differ-
ent polymers were synthesized. Multivalent aptamer polymers were synthesized with
either SKBR3-R1Tr1 or SKBR3-R1Tr2 using a ratio of 1:225 (aptamer:acrylamide monomer,
Figure 5A). Dox boxes were incorporated as double-stranded (2sDox) or hairpin (hpDox)
modules using a ratio of 1:2.5:225 (DNA:Dox:acrylamide). For microscopic imaging exper-
iments, Alexa Fluor 594 (AF594) modified aptamers (ratio 1:5) or fluorophore modified
hairpin Dox boxes (ratio 1:10) were co-polymerized. The sequences of the Dox boxes were
designed such that each hairpin module contains six intercalation sites for Dox loading,
and each double-stranded Dox box nine (Figure 2B).
First, binding and internalization of the polymeric aptamers was assessed. As ob-
served for free aptamers, polymers functionalized with SKBR3-R1Tr (AA-SKBR3-R1Tr)
readily internalize after 24 h in SKBR3 cells grown as 3D spheroids or as 2D tissue and
do not internalize into MCF10A cells (Figure 6). Next, the potential toxicity of free and
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multimeric aptamers was investigated, as this can be a major concern in designing ther-
apeutic agents. Viability tests were conducted using a CellTiter Glo-3D® viability assay.
Neither the free aptamers nor the polymeric aptamers with unloaded Dox boxes induced
cytotoxicity after 8 days of incubation, as shown in Figure 7.




Figure 4. Panel (A): Images of SKBR3 spheroids (top row) and MCF10A spheroids (bottom row) 
incubated with truncated SKBR3-R1Tr-AF594 aptamers. Spheroids in the images on the left were 
incubated for 24 h with aptamers and spheroids in the middle images for 48 h. The images on the 
right include the bright field images of the 48 h incubations. Panel (B): Images of SKBR3 cells (left) 
and MCF10A cells (right) grown in 2D in chamber slides, incubated with truncated SKBR3-R1Tr-
AF594 aptamers. Cells were incubated for 48 h with aptamers and images were acquired at 100x 
magnification. 
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has been used in a variety of anticancer treatment including breast cancer [20]. Dox acts 
by intercalating DNA, which causes disruption of DNA replication and finally results in 
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Figure 4. Panel (A) Images of SKBR3 spheroids (t p row) and MCF10A spheroids (bottom row)
incubated with truncated SKB 3-R1Tr-AF594 aptamers. Spheroids in the images on the left were
incubated for 24 h with aptamers and spheroids in the middle images for 48 h. The images on
the right include the bright field images of the 48 h incubations. Panel (B) Images of SKBR3 cells
(left) and MCF10A cells (right) grown in 2D in chamber slides, incubated with truncated SKBR3-
R1Tr-AF594 aptamers. Cells were incubated for 48 h with aptamers and images were acquired at
100× magnification.
Third, we assessed Dox toxicity by adding free Dox directly to SKBR3 and MCF10A
spheroids at increasing Dox concentrations (Supplementary Figures S7 and S8). Increased
toxicity is observed with increasing concentrations of Dox up to 2 µM after 8 days of incuba-
tion for both the target SKBR3 and control MCF10A spheroids. At a concentration of 2 µM
free Dox, the survival rate levels off to 1–2% (Supplementary Figure S8). This concentration
was used to investigate the effect of targeted delivery of Dox using polym ric aptamers.
Loading of Dox in stoichiometric amounts to multimeri constructs with either hairpin or
double stranded Dox boxes wa determined using a fluorescenc assay (Supplementary
Figure S9). Targete delivery of 2 µM Dox, contained within the pol meric constructs, was
u ed by polymer conce tration. Targeted livery and specific cell death using the poly-
meric constructs was a hieved for all polymeric constructs tested (Figure 7). The highest
specificity and efficacy in cell death was observ d for the polymeric constr cts
c ntaining the doubl stranded Dox boxes (Figure 7). The specific cytotoxic effect on SKBR3
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spheroids is also clearly illustrated by confocal microscope images, which show disrupted
SKBR3 cells and healthy, unaffected MCF10A cells after 2–3 days of incubation (Figure 8).
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hairpin Dox Boxes (hpDox) or 2-strand Dox boxes (2sDox) and acrylamide in a ratio 1:2.5:225. In 
the case of the hairpin Dox boxes, one in every 10 Dox boxes is labeled with Alexa Fluor 594 (red 
star). Dox is indicated as orange ovals. 
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Figure 5. (A) Schematic of truncated SKBR3-R1 (Apt) co-polymerized with acrylamide. Spacing
between each aptamer is ~225 acrylamide monomers and one in every five aptamers is labeled with
Alexa Fluor 594 (red star). (B) Schematic of truncated SKBR3-R1 (Apt) co-polymerized with hairpin
Dox Boxes (hpDox) or 2-strand Dox boxes (2sDox) and acrylamide in a ratio 1:2.5:225. In the case of
the hairpin Dox boxes, one in every 10 Dox boxes is labeled with Alexa Fluor 594 (red star). Dox is
indicated as orange ovals.
Finally, we assessed therapeutic specificity by targeting polymeric aptamers with
loaded Dox boxes to a number of different breast cancer cell lines representing different
subgroups (Figure 9). Of these, the SKBR3 cells, HCC202, and HCC1954 are HER2+, T47D,
and MCF7 are Luminal A (ER+, PR+, HER2-), and MDA-MB231 is triple negative (TNBC).
As Figure 9 shows, the highest efficacy in cell death is achieved for the target SKBR3 cells.
High efficacy is also observed for the other two breast cancer cell lines that overexpress
HER2, i.e., HCC202 and HCC1954. MDA-MB-231, which is negative in ER, PR, and HER2
is the least affected by incubation with Dox loaded polymers, but still has a viability of only
50–80%, depending on Dox box type and Dox doses. Of the two luminal A cell lines, T47D
shows a response as high as the HER2+ cell lines, while MCF7 shows a response in between
the HER2+ and triple negative cell line (30–45% viability). HER2 is highly overexpressed
on the surface of SKBR3 cancer cells [38,39], and would therefore be considered a likely
candidate for the specific binding target of our raised aptamers. However, these results, in
particular the observed high response of T47D and MCF7, suggest that the binding target
for the selected aptamers is some other receptor, which after aptamer binding mediates
internalization of the polymeric constructs, containing payloads of Dox.
2.5. Im ging of Breast Cancer Tissue with Aptamers
To assess the applicability of these aptamers in breast cancer diagnosis and their
specificity we selected 4 formalin-fixed paraffin embedded breast cancer tissues and stained
these with SKBR3-R1 and control scrambled aptamer (Figure 10). Whereas one tissue was
negative, the other showed specific (peri) nuclear staining of breast cancer cells suggesting
the aptamer is specific for particular cancers.




Figure 6. Panel (A): Images of SKBR3 spheroids (top row) and MCF10A spheroids (bottom row) 
incubated with truncated SKBR3-R1Tr-AF594 aptamers on polyacrylamide (1:225). Spheroids in 
the images on the left were incubated for 24 h with aptamer polymers and spheroids in the middle 
images for 48 h. The images on the right include the bright field images of the 48 h incubations. 
Panel (B): Images of SKBR3 cells (left) and MCF10A cells (right) grown in 2D in chamber slides, 
incubated with truncated SKBR3-R1Tr-AF594 aptamers on polyacrylamide (1:225). Cells were in-
cubated for 48 h with aptamers and images were acquired at 100× magnification. 
Third, we assessed Dox toxicity by adding free Dox directly to SKBR3 and MCF10A 
spheroids at increasing Dox concentrations (Supplementary Figures S7 and S8). Increased 
toxicity is observed with increasing concentrations of Dox up to 2 µM after 8 days of in-
cubation for both the target SKBR3 and control MCF10A spheroids. At a concentration of 
2 µM free Dox, the survival rate levels off to 1–2% (Supplementary Figure S8). This con-
centration was used to investigate the effect of targeted delivery of Dox using polymeric 
aptamers. Loading of Dox in stoichiometric amounts to multimeric constructs with either 
hairpin or double stranded Dox boxes was determined using a fluorescence assay (Sup-
plementary Figure S9). Targeted delivery of 2 µM Dox, contained within the polymeric 
constructs, was tuned by polymer concentration. Targeted delivery and specific cell death 
using the polymeric constructs was achieved for all polymeric constructs tested (Figure 
7). The highest specificity and efficacy in targeted cell death was observed for the poly-
meric constructs containing the double stranded Dox boxes (Figure 7). The specific cyto-
toxic effect on SKBR3 spheroids is also clearly illustrated by confocal microscope images, 
which show disrupted SKBR3 cells and healthy, unaffected MCF10A cells after 2–3 days 
of incubation (Figure 8). 
Figure 6. Panel (A) Images of SKBR3 spheroids (top row) and MCF10A spheroids (bottom row)
incubated with truncated SKBR3-R1Tr-AF594 aptamers on polyacrylamide (1:225). Spheroids in
the images on the left were incubated for 24 h with aptamer polymers and spheroids in the middle
images for 48 h. The images on the right include the bright field images of the 48 h incubations. Panel
(B) Images of SKBR3 cells (left) and MCF10A cells (right) grown in 2D in chamber slides, incubated
with truncated SKBR3-R1Tr-AF594 aptam rs on polyacrylamide (1:225). Cells were incubated for
48 h with aptamers and images were acquired at 100× magnification.




Figure 7. Cell viability of SKBR3 and MCF10A spheroids after 8 days of incubation with polymeric 
SKBR3-R1Tr or SKBR3-R2Tr aptamers and Dox boxes charged with doxorubicin. The text below 
the bars indicates the aptamer used and the Dox load, PAA indicates cells treated with multimeric 
aptamer polymers, conjugated to polyacrylamide. Cell viability was calculated relative to un-
treated spheroids (DBPS). * Statistical significant difference between MCF10A and SKBR3 (p < 
0.01). 
Finally, we assessed therapeutic specificity by targeting polymeric aptamers with 
loaded Dox boxes to a number of different breast cancer cell lines representing different 
subgroups (Figure 9). Of these, the SKBR3 cells, HCC202, and HCC1954 are HER2+, T47D, 
and MCF7 are Luminal A (ER+, PR+, HER2-), and MDA-MB231 is triple negative (TNBC). 
As figure 9 shows, the highest efficacy in cell death is achieved for the target SKBR3 cells. 
High efficacy is also observed for the other two breast cancer cell lines that overexpress 
HER2, i.e., HCC202 and HCC1954. MDA-MB-231, which is negative in ER, PR, and HER2 
is the least affected by incubation with Dox loaded polymers, but still has a viability of 
only 50–80%, depending on Dox box type and Dox doses. Of the two luminal A cell lines, 
T47D shows a response as high as the HER2+ cell lines, while MCF7 shows a response in 
between the HER2+ and triple negative cell line (30–45% viability). HER2 is highly over-
expressed on the surface of SKBR3 cancer cells [38,39], and would therefore be considered 
a likely candidate for the specific binding target of our raised aptamers. However, these 
results, in particular the observed high response of T47D and MCF7, suggest that the bind-
ing target for the selected aptamers is some other receptor, which after aptamer binding 
mediates internalization of the polymeric constructs, containing payloads of Dox.  
Figure 7. Cell viability of SKBR3 and MCF10A spheroids after 8 days of incubation with polymeric
SKBR3-R1Tr or SKBR3-R2Tr aptamers and Dox boxes charged with doxorubicin. The text below
the bars indicates the aptamer used and the Dox load, PAA indicates cells treated with multimeric
aptamer polymers, conjugated to polyacrylamide. Cell viability was alculated relative to untreated
spheroids (DBPS). * Statistic l ignifica t differenc betwe n MCF10A and SKBR3 (p < 0.01).
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Figure 8. Images of SKBR3 spheroids (left half of each image set) and MCF10A spheroids (right 
half of each image set) incubated with polymeric SKBR3-R1Tr aptamers and Dox loaded Dox 
boxes (see Figure 2 and main text) for, respectively, 48 and 72 h. Panel (A): SKBR3-R1Tr + hairpin 
Dox box (hpDox) of which 1 in every 10 Dox boxes is Alexa Fluor 594 labeled. Panel (B): SKBR3-
R1Tr + 2-strand Dox box (2sDox). The bottom row of each panel is the bright field image of the 
fluorescent image above. 
Figure 8. Images of SKBR3 spheroids (left half of each image set) and MCF10A spheroids (right
half of each image set) incubated with polymeric SKBR3-R1Tr aptamers and Dox loaded Dox boxes
(see Figure 2 and main text) for, respectively, 48 and 72 h. Panel (A) SKBR3-R1Tr + hairpin Dox
box (hpDox) of which 1 in every 10 Dox boxes is Alexa Fluor 594 labeled. Panel (B) SKBR3-R1Tr +
2-strand Dox box (2sDox). The bottom row of each panel is the bright field image of the fluorescent
image above.
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3. Discussion
Several aptamers have previously been generated in the context of breast cancer, using
peptides or purified receptor proteins [40–52], receptors overexpressed on engineered
cell lines [53–55], or breast cancer cell lines as targets [56–64]. However, none of these
aptamers have been selected using live 3D spheroids as targets. In this study, we used
3D spheroids of SKBR3 breast cancer cells as targets for aptamer selection, as these are
a better mimic for the natural environment of solid tumors than the commonly used 2D
tissue cultures, and should thus serve as a better model for selecting aptamers directed
at breast cancer cells in vivo [11,12]. Using spheroids as targets, we were able to select
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DNA aptamers that bind SKBR3 cells with high affinity and specificity and display higher
affinity for SKBR3 cells, grown as 3D spheroids than SKBR3 cells, grown as 2D monolayers.
A few studies have been reported earlier in which aptamers were selected against SKBR3
cancer cells by Cell-SELEX [59,62]. However, in these studies, 2D tissue cultures were
used as targets for selection and the aptamers were primarily used for binding studies and
molecular subtyping of breast cancer. Neither report demonstrated therapeutic value of
the selected aptamers.
The concept of multivalency, where multiple ligands bind simultaneously to multiple
targets, in particular to receptors on a cell surface, has been used for enhancing binding
affinity of aptamers in different contexts and designs [64–67]. Various types of constructs
have been designed to achieve multivalency: Multimeric constructs, connected with nucleic
acid, peptide, or artificial linkers [37,48,68–73] of predefined length to tune the spacing in
between aptamers, or nanoparticles [35,43,74–79] or liposomes [62,64,80–82] decorated with
aptamers with pre-defined density. Polymeric designs as we report here have not been used
widely in the construction and application of multimeric aptamers [37,70–73]. This design
has several advantages. The spacing and valency of the aptamers can be easily tuned using
appropriate monomeric ratios during the polymerization step. Moreover, the design allows
for convenient incorporation of small DNA units for functionalization, e.g., with fluorescent
dyes, or as drug carriers for specific treatment. This is far more efficient in synthesis
and functionalization than extending selected aptamers for subsequent functionalization.
Importantly, the polymeric constructs without loaded Dox did not confer cytotoxicity
to the control cells, which is critical for using the polymeric constructs as a vehicle for
therapeutics. Although we have not yet explored the added value of multivalency in
affinity and specificity, this is likely to occur and can be a topic to be addressed in a next
step of this research.
Due to the serious side effects of systemic chemotherapy, the targeted delivery of drugs
using aptamers as vehicle by covalent conjugation of aptamers with small molecule anti-
cancer drugs has been a major research topic in the aptamer field [7,8]. By taking advantage
of the ability of doxorubicin to intercalate into CG-rich sequences (20-22) combined with
our modular design, we created an efficient platform for drug delivery without the need
for chemical conjugation. The results show that the polymeric aptamers with Dox boxes are
selectively delivered to breast cancer cells and internalized, after which Dox accumulates
in the nucleus. Treatment with these polymers carrying payloads of doxorubicin results in
breast cancer cell death only, while non-malignant breast cells largely survive. Compared
to earlier studies [25–35,47,64,71,75,78,79,81,82], the response to selective treatment with
doxorubicin is high, resulting in <5% cell survival of SKBR3 spheroid cells at a dose of
2 µM. Taken together, these results illustrate the high potential of our multimeric approach
in breast cancer therapy.
4. Materials and Methods
4.1. Cell lines and Cultures
SKBR3, T47D, MCF7, and MDA-MB231 cell lines were obtained from LCG Pro-
mochem (London, UK). MCF10A cells were obtained from LCG Promochem (London, UK).
HCC1954 and HCC202 were a kind gift from John Martens (Erasmus MC, Rotterdam, The
Netherlands). Cells were cultured at 37 ◦C, 5% CO2 in Dulbecco’s modified Eagles medium,
high glucose, Glutamax supplemented with 10% (v/v) fetal bovine serum, 1 mM sodium
Pyruvate, 1x non-essential amino acids, and 50 Units penicillin, 50 µg streptomycin (all
from Gibco, ThermoFisher Scientific, Landsmeer, The Netherlands). MCF10A cells were
cultured in Dulbecco’s modified Eagles medium, Nutrient Mixture F-12 (DMEM/F-12),
supplemented with 5% Horse serum, 10 Units penicillin, 10 µg streptomycin (Gibco),
10 µg human EGF, 5 mg Insulin, 0.05 mg Cholera Toxin, 1 mM Dexamethasone (all from
Sigma-Aldrich, Zwijndrecht, The Netherlands).
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4.2. Spheroid Preparation
Multicellular tumor spheroids were prepared from conventional monolayer cultures
using the adaptive overlay technique [10]. Briefly, 10,000 cells were added per well in ultra-
low attachment 96-well plates (Corning, Corning, NY, USA) in 100 µL standard culture
medium with 2.5% Matrigel (BD Biosciences, San Jose, CA, USA). After a centrifugation
step at room temperature (10 min at 1000× g) 100 µL culture medium was added and cells
were allowed to form spheroids for 5 days.
4.3. Selection Procedure
The random DNA library and all other oligonucleotides (Supplementary Table S1)
were purchased from IDT (Leuven, Belgium) and purified in house using denaturing PAGE.
The Cell-SELEX procedure was carried out as described by Sefah et al. [83] with minor mod-
ifications. In the first two rounds of selection, 5 million SKBR3 cells grown to confluency
were used as positive target cells and 10 million MCF10A cells for negative selection. From
the third round on, 1 million SKBR3 cells grown in spheroids were used for the positive
selection and further negative selections were omitted. The binding stringency in each
round of selection was increased by lowering the amount of DNA for binding, shortening
the time of binding, and increasing the percentage of fetal bovine serum (FBS), the wash-
ing time, and washing volume (Supplementary Table S2). Since the cells were grown in
spheroids, FACS analysis was not readily applicable to monitor the selection progress and
selection was therefore continued blindly for a total of 12 rounds. The adapter sequences
of the DNAs obtained after each selection round were extended by PCR with barcoded
primers suitable for multiplexed next generation sequencing (Supplementary Table S1) and
native PAGE purified PCR products were sequenced on an Illumina HiSeq2000 platform
(ServiceXS, Leiden, The Netherlands). Raw sequencing data was processed and analyzed
using the public data server at www.usegalaxy.org (accessed on 3 February 2017) [84].
4.4. Fluorescent Labeling of Truncated Aptamer DNAs
DNA aptamers for labeling purposes were purchased from IDT with a 3’-terminal
ribose. The terminal 3’-ribonucleotides of the aptamer DNAs were oxidized by incubating
10 µM of DNA in 100 mM NaAc (pH 5.2) containing 250 µM freshly prepared NaIO4
for 30 min on ice. After 2-fold dilution of the reaction mixture and adjustment of the
NaAc (pH 5.2) concentration to 300 mM, the DNA was precipitated with 2-propanol and
the pellet washed with ice-cold 70% ethanol and subsequently air dried. The DNA was
dissolved to 10 µM in 100 mM NaAc (pH 5.2) containing 100 µM Alexa Fluor hydrazide
594 and incubated for 60 h at 4 ◦C in the dark. The DNA was subsequently purified from
the uncoupled label by precipitation with 2-propanol and thorough rinsing of the pellet
with ice-cold 70% ethanol. The full-length aptamer DNAs were first equipped with a
3’-ribonucleotide by ligating a 13-nt oligonucleotide, representing the terminal part of the
3’-adapter sequence to the rest of the aptamer because of sequence length restrictions of
the commercially available oligonucleotides. Ligations were carried out at 10 µM of a
stoichiometric DNA assembly that was heat annealed prior to the addition of T4 DNA
ligase and incubated for 3 h at 37 ◦C. Ligation products were purified using denaturing
PAGE prior to subjecting the DNAs to the fluorescent labeling procedure. All fluorescent
labeling yields were 85–95% as determined by UV-VIS spectroscopy using a Nanodrop
spectrophotometer (IsogenLife Science, De Meern, The Netherlands).
4.5. Co-Polymerisation of DNA with Acrylamide
5’-Acrydite modified truncated aptamers were co-polymerized with acrylamide in a mo-
lar ratio of 1:225 (DNA: acrylamide) alone or in combination with hairpin Dox boxes (hpDox)
or 2-strand Dox box lead strand (2sDox-lead) in a ratio of 1:2.5:225 (DNA:Dox:acrylamide).
For microscopic imaging experiments, an Alexa Fluor 594 (AF594) modified aptamer (ratio
1:5) or hairpin Dox box (ratio 1:10) was co-polymerized. In general, 10 nmol of aptamer
DNA was dried in a Speed-Vac (Thermo-scientific), either alone or mixed with 22.5 nmol of
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hpDox or 2sDox-lead. The dried DNA was dissolved in 16 µL of a freshly prepared solution
of 1% acrylamide (140 mM) in Dulbecco’s PBS (DPBS), mixed well and supplemented with
0.5 µL of freshly prepared solutions of 10% APS and 10% TEMED. Polymerization was
carried out overnight at 25 ◦C, 500 rpm in a Thermoshaker (Eppendorf). The next day, extra
portions of TEMED and APS were added and polymerization was continued for 5 h at
37 ◦C, 500 rpm in a Thermoshaker. The volume was adjusted with DPBS to 500 µL resulting
in a 20 µM solution with respect to the aptamer DNA. The degree of co-polymerization
was ≥90% as confirmed by visualization on denaturing PAGE (Supplementary Figure S10).
4.6. Binding, Internalization, and Doxorubicin Loading Capacity Assays
For binding assays, stock solutions of free and/or polymeric DNA aptamer were
prepared by snap-cooling a boiling (95 ◦C) solution of 5 µM aptamer DNA in DPBS with
5 mM MgCl2 (DPBS-Mg) on ice water. Three spheroids were carefully pipetted out of the
96-well plate using end-cut 200 µL filter tips and pooled together in a microcentrifuge
tube and allowed to settle on the bottom. Supernatant was carefully pipetted off and
the spheroids were washed twice with 200 µL of binding buffer (DPBS, 5 mM MgCl2,
22.5 mM D-glucose, 1 mg/mL BSA, and 100 µg/mL tRNA (Baker’s Yeast)). 100 µL of
50 nM aptamer solution in binding buffer was added to the spheroids and incubated
for 1 h at room temperature with occasional swirling of the spheroids, taking care not to
disturb the spheroid structure. Spheroids were washed once with 200 µL of binding buffer
and then incubated for 20 min in 200 µL of 1 µg/mL Hoechst 33342 in binding buffer for
nuclei staining. Spheroids were transferred to an epoxy resin masked 6-well microscopy
slide (Marienfeld, #1215130). Excess of binding buffer was pipetted off and spheroids
were included with Fluoromount G (Invitrogen, Carlsbad, CA, USA) under a coverslip.
For internalization and doxorubicin loading capacity assays, stock solutions of free and/or
polymeric DNA aptamers (with or without Dox Boxes) were prepared in DPBS-Mg at
1 µM with respect to the aptamer DNA concentration. In case of the 2-strand Dox box, a
stoichiometric amount of 2sDox-lag (complementary to 2sDox-lead) was added prior to
heat-annealing. When required for the experiment, doxorubicin was added to the desired
concentration after heat-annealing of the DNAs from a freshly prepared 100 µM solution
in DPBS-Mg produced out of a 5 mM DMSO stock. For internalization assays, (polymeric)
DNA aptamers were added at 100 nM to the growth medium of 2D cell cultures grown in
8-well chamber slides and/or to the growth medium of spheroids in 96-well plates and
incubated for 24, 48, and/or 72 h. Spheroids were then harvested, washed, and stained
with Hoechst prior to inclusion on microscopy slides as described above.
4.7. Confocal Laser Scanning Microscopy
All microscopy experiments were carried out on a Sp8x confocal laser scanning
microscope equipped with a 405 nm diode laser and a pulsed white light laser (Leica
microsystems) using 10× Air, 20× Air, and 100× Oil magnification objectives. For the
binding assays and the 2D internalization assay, microscope settings were: 50% laser power,
6% shutter intensity for the 405 nm laser line, and 5% for the 594 nm laser line, respectively.
Images were acquired consecutively to prevent cross talk between dye excitations or
bleeding of emissions in different channels. The scan speed was 200 Hz and the fluorescent
signal was visualized using hybrid detectors in BrightR mode, with line accumulation and
frame averaging set to three. Settings for the 3D internalization assays were identical, but
the shutter intensities were 3% for the 405 nm laser line and 10% for the 594 nm laser line,
or 485 nm laser line for doxorubicin excitation. Images were acquired and processed using
LasX software, version 1.8.1.13759 (Leica, Wetzlar, Germany).
4.8. In Vitro Cytotoxicity Assays
Polymeric aptamers co-polymerized with Dox boxes were prepared and loaded with
doxorubicin to the desired concentrations as described above. The growth medium of
8-days old spheroids was supplemented with polymeric aptamers to 100 nM with respect
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to the DNA aptamer (250 nM Dox box) in sextuple and incubated for another 8 days at
37 ◦C, 5% CO2 in the incubator stove. On day four, 50% (100 µL) of the medium was
replaced by fresh medium and an extra dose of doxorubicin loaded polymeric aptamers
was added to 50 nM. After 8 days, spheroids were individually transferred in 100 µL
of medium to a luminescence plate (Thermo Scientific, #9502887) and mixed thoroughly
with 100 µL of CellTiter-Glo® 3D (Promega, Madison, WI, USA). This was incubated for
45 min at 70 rpm on an orbital shaking platform at room temperature in the dark, and the
chemiluminescence was read in a Victor3 plate reader (PerkinElmer, Waltham, MA, USA).
Similarly, doxorubicin titration curves were generated for SKBR3 and MCF10A spheroids
to determine the optimal doxorubicin dose.
4.9. Preparation and Imaging of Breast Cancer Tissue
Paraffin embedded fixated breast cancer tissue was cut into 5-micron sections. Sections
were dewaxed, rehydrated, and washed with demineralized water and subsequently
incubated in citrate buffer (pH 6.0) at 96 ◦C for 30 min (HIER—heat induced epitope
retrieval), allowed to cool down to room temperature, and then rinsed with demineralized
water. Sections were pre-incubated with binding buffer (DPBS-Mg + 4.5 g/L D-glucose)
for 30 min at room temperature. 200 µL of 100 nM SKBR3R1-AF594 or Scramble-AF594
in binding buffer was added to the sections and incubated for 1 h at room temperature.
Sections were rinsed with binding buffer, counterstained with Hoechst 33342 (nuclear
staining) for 5 min at room temperature, and coverslipped with Fluoromount. Images were
acquired using Ivision-Mac on a Zeiss AXIO Scope A1.
4.10. Statistical Analysis
Data were analyzed using GraphPad Prism 5 and are shown as mean + standard
deviation. Statistical significance of differences between 2 groups was assessed using
Student’s t-tests, with discovery determined using the two-stage linear step-up procedure
of Benjamini, Krieger, and Yekutieli [85], with Q = 1%. Differences between more than
2 groups were established using one-way ANOVA with Bonferroni corrected post hoc tests.
Statistical significance was assumed a priori at α = 0.01.
5. Conclusions
In summary, we have developed an innovative modular DNA aptamer platform based
on 3D cell- SELEX and polymer multivalency. We successfully selected DNA aptamers with
high affinity by targeting spheroids of SKBR3 breast cancer cell lines. By copolymerization
of selected DNA aptamers with Dox containers efficient vehicles with high loading capacity
were constructed for targeted drug delivery. Fluorescence imaging and viability tests
showed high specificity and efficacy of the polymeric DNA aptamer platforms. Most
importantly, targeted delivery of doxorubicin using multivalent aptamer-Dox box polymers
to breast cancer spheroids resulted in high selective toxicity. Given the high affinity,
selectivity, and cytotoxic efficacy, the polymeric modular platform holds great promise for
diagnostics and treatment of breast cancer.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ph14040349/s1. Table S1: Overview of used oligonucleotides, Table S2: Summary of the
aptamer selection procedure, Table S3: Abundance and alignment of the top 10 DNA aptamers,
Table S4: Percentages of enrichment of the top 5 DNA aptamers in the 12 rounds of selection,
Figure S1: Secondary structure models of the top 10 DNA aptamers, Figure S2: Z-stacks of SKBR3
and MCF10A spheroids, incubated with full SKBR3-R1 aptamer, Figure S3: Images of SKBR3 and
MCF10A spheroids, incubated with randomized aptamer (scramble-AF594), Figure S4: Binding curve
of aptamer SKBR3-R1Tr to SKBR3 spheroids, Figure S5: Internalization experiment of SKBR3 and
MCF10A spheroids with randomized aptamer, Figure S6: Mechanism of aptamer internalization,
Figure S7: Images of SKBR3 and MCF10A spheroids with free Doxorubicin, Figure S8: Effect of free
Doxorubicin concentrations on the viability of SKBR3 and MCF10A spheroids, Figure S9: Determina-
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tion of the doxorubicin load of polymeric aptamer constructs with and without hairpin Dox boxes
and 2-strand Dox boxes, Figure S10: Quality check of co-polymerization of polymeric constructs.
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